GLENMARK Glenmark Pharmaceuticals Q4 FY26 results (Jan–Mar 2026) and concall
Glenmark Pharmaceuticals reported a strong Q4 and FY26, with consolidated revenue growing 15.8% and 27.5% YoY respectively. Key achievements include a significant licensing deal for ISB 2001, achieving a gross debt-free balance sheet, and robust growth in global brands like RYALTRIS. While the U.S. market faced temporary headwinds in Q4, the company anticipates strong growth in FY27 driven by new product launches and strategic investments across key markets.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 6.8%, net profit down 150.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 2,636 | 2,251 | 2,010 | 2,395 | 1,539 −42% | 2,360 +5% | 2,147 +7% |
| EBITDA | 779 | 494 | 341 | 728 | -178 −123% | 496 +0% | 32 −91% |
| Net profit | 595 | 414 | 148 | 330 | -739 −224% | 282 −32% | -74 −150% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
